Evaluation of Anti-Tumour Efficacy of Liposomes Loaded with Rubitecan as Potential Antitumor Drug Delivery System

Aim: The present research objective was to characterize the prepared liposomes for in vitro cytotoxicity assay, cellular uptake studies of liposomes, competitive binding assay and hemolytic test. Materials and Methods: The prepared liposomes were assessed for the cellular cytotoxicity of Rubitecan-loaded liposomes on cancer cell linings. Results: The images infer that the uptake of liposomes had a significant time-dependent fusion method for cellular internalization-quantitative analysis of cellular uptake determined by flow cytometry. The fluorescence intensity profile is correlated with the results obtained in laser scanning confocal microscopic study. The results inferred that the conjugated transferrin liposomes entered the cells by surface adherence were facilitated by endocytosis mediated by the transferrin receptor. The hemolysis value of Tf-Lip/ Rubitecan was less than 2%, which indicated that it had great haemo-compatibility and could be safe for intravenous injection. Conclusion: This work effectively created and optimized a novel transferrin liposome conjugated anti-tumor targeted drug delivery system using Rubitecan as an anticancer agent. The study’s findings suggest that transferrin-targeted liposomes enhanced the delivery of Rubitecan to the tumor, potentially enhancing the drug’s anticancer efficacy in clinical settings. Keywords: Rubitecan, Transferrin, CCK-8, Cellular uptake, Cellular Internalization.